The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer.
J. L. Vardy
No relevant relationships to disclose
G. R. Pond
No relevant relationships to disclose
A. Dodd
No relevant relationships to disclose
D. Warr
No relevant relationships to disclose
B. Seruga
No relevant relationships to disclose
M. J. Clemons
No relevant relationships to disclose
L. Bordeleau
No relevant relationships to disclose
I. Tannock
No relevant relationships to disclose